BRIEF — Roche Receives FDA's Approval For Its Enspryng, A First — In — Class IL — 6R Inhibitor

Oct 16 (Reuters) — ROCHE HOLDING AG: Fda Approves Roche’s Enspryng, A First-in-class Il-6r Inhibitor, As The First And Only At-home Subcutaneous Treatment Option For Thyroid Eye Disease (Ted) Roche Holding Ag - Enspryng Offers First At-home Subcutaneous Treatment Option For Ted Roche Holding Ag - Fda Approval Based On Phase Iii Satrago-1 And -2 Studies Roche Holding Ag - Ted Affects About 155 Out Of Every 100,000 People In The Us Source text:... Further company coverage: ROPC.S (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;)